GeoVax Labs(GOVX) - 2025 Q1 - Quarterly Results

Exhibit 99.1 GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update COVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025 Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to initiate in second half of 2025 Gedeptin® advancing into Phase 2 clinical trial of as treatment for first recurrent head and neck cancer in combination w ...